AstraZeneca PLC (AZN)
| Market Cap | 245.13B +6.8% |
| Revenue (ttm) | 61.37B +8.6% |
| Net Income | 10.45B +25.9% |
| EPS | 6.68 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 23.47 |
| Forward PE | 14.59 |
| Dividend | $3.23 (2.04%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 4,326,139 |
| Open | 157.68 |
| Previous Close | 158.75 |
| Day's Range | 157.12 - 159.02 |
| 52-Week Range | 146.10 - 212.71 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 213.69 (+34.82%) |
| Earnings Date | Jul 27, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $213.69, which is an increase of 34.82% from the latest price.
News
AZN Looks 12.3% Undervalued on GF Value⢠Amid Dividend Strength and Insider Selling
AZN Looks 12.3% Undervalued on GF Value⢠Amid Dividend Strength and Insider Selling
Investor backlash killed AstraZeneca, Bristol Myers tie-up, FT reports
AstraZeneca (AZN) CEO Pascal Soriot had been quietly pursuing a transformative deal and held serious talks with Bristol Myers (BMY) over a potential mostly stock-based acquisition at a premium, despit...
AstraZeneca (AZN) Pursues Major Merger with Bristol-Myers Squibb
AstraZeneca (AZN) Pursues Major Merger with Bristol-Myers Squibb
AstraZeneca's Failed $400 Billion Merger Talks with Bristol Myers Squibb
AstraZeneca's Failed $400 Billion Merger Talks with Bristol Myers Squibb
AZN Looks 10.2% Undervalued on GF Value⢠as Dividend Remains Sustainable
AZN Looks 10.2% Undervalued on GF Value⢠as Dividend Remains Sustainable
AIM ImmunoTech Reports Q2 Loss, Topline Phase 2 Pancreatic Cancer Data Due In Q1 2027
(RTTNews) - AIM ImmunoTech Inc. (AIM) has reported its second-quarter 2026 financial results and provided a business update, highlighting progress in its Phase 2 DURIPANC clinical trial evaluating Amp...
Hamish McRae: Why Britain's FTSE giants find it so hard to crack America
From Tesco's Fresh & Easy adventure, to HSBC and M&S's ambitions and giant mergers, making it big in the US is not easy, hence market disdain for AstraZeneca's idea.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to conta...
AstraZeneca (AZN) Explores Merger Talks with Bristol-Myers Squibb
AstraZeneca (AZN) Explores Merger Talks with Bristol-Myers Squibb
AstraZeneca may buck a decade of pharma strategy to buy U.S. scale
Reported talks of a tie-up between two industry giants could deliver instant U.S. scale for AstraZeneca through Bristol Myers Squibb's U.S.-centric business, but at the cost of slower growth and integ...
Deal or No Deal, AstraZeneca Stock Is a Bargain
The logic of a pharma megamerger is questionable, but AstraZeneca's record isn't.
AstraZeneca PLC (AZN) Stock Up 3.8% and Still Undervalued -- GF Score: 83/100
AstraZeneca PLC (AZN) Stock Up 3.8% and Still Undervalued -- GF Score: 83/100
AstraZeneca shares rise as fresh reports deny mega-merger talks with US rival
Astra's stock climbed 2.5% or 296p to 12,036p after Reuters quoted a senior source at the business quashing rumours of any potential tie-up.
Soriot should explain the curious case of AstraZeneca’s non-deal
AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders Hold the heartburn pills. It seems AstraZeneca is no longer contempl...
No $400B Mega Merger? AstraZeneca Rises, Bristol Myers Falls as Report Denies Deal
Shares in British pharma giant AstraZeneca ($AZN) jumped about 5% on Wednesday morning while those in top U.S. biopharma company Bristol Myers ($BMY) fell by more than 3%. This came…
Bristol Myers, AstraZeneca not engaged in merger talks, Reuters reports
AstraZeneca (AZN) and Bristol Myers (BMY) are not engaged in merger discussions, ending speculation around a potential $400B pharmaceutical combination, Reuters’ Maggie Fick and Sabrina Valle report. ...
Reminder - AstraZeneca (AZN) Goes Ex-Dividend Soon
Looking at the universe of stocks we cover at Dividend Channel, on 8/7/26, AstraZeneca plc (Symbol: AZN) will trade ex-dividend, for its semi-annual dividend of $0.795, payable on 9/8/26. As a percent...
'No discussions' over AstraZeneca-Bristol Myers deal, senior source says
There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to...
AZN Looks 14.6% Undervalued on GF Valueâ¢
AZN Looks 14.6% Undervalued on GF Valueâ¢
AstraZeneca deal talks with Bristol Myers remain active, Semafor says
AstraZeneca’s (AZN) merger talks with Bristol Myers (BMY) remain active, Liz Hoffman of Semafor reports. A potential deal would move AstraZeneca’s revenues further away from the UK and Europe and…
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
BOSTON and ROLLE, Switzerland, Aug. 4, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) s...
More Biotech M&A Is on the Way, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued
Is AstraZeneca PLC (AZN) a Bargain After 6.9% Drop? GF Value Says Undervalued
Goldman Sachs's Hader on why AstraZeneca's stock fell on news of possible merger with Bristol Myers
Asad Haider, Goldman Sachs Healthcare Analyst, joins 'Closing Bell Overtime' to talk a possible merger between Bristol Myers and AstraZeneca.